Eli Lilly and Company announced the successful completion of its acquisition of Morphic Holding, Inc. Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious ...

Eli Lilly is acquisitive, too, and just purchased a company called Morphic Holding ... Eli Lilly looks like a great stock to buy and hold for the long run, while its top-notch track record ...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) has finalized its purchase of biopharmaceutical firm Morphic Holding, Inc. (NASDAQ: NASDAQ:MORF), a move aimed at enhancing its portfolio of ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The ...

The maintained Buy rating and price target signal confidence in Eli Lilly's continued growth and ... The company has also completed the acquisition of Morphic Holding (NASDAQ:MORF), Inc., adding ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,025.00. The company’s shares closed last Friday at $922.12.

Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 ...

2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company ...